Close Menu

antisense

In Science this week: crystal structures of single-stranded RNA bacteriophages found through metagenomic studies, more.

In PNAS this week: effect of premature termination codons in the DMD gene, knock-down of DUX4 in facioscapulohumeral muscular dystrophy, and more.

As part of the deal, Ionis also took a $10 million equity stake in Empirico and was the lead investor in the company's Series A-2 financing round.

UMich's Arul Chinnaiyan plans to use the funding to develop new tools and technologies to identify biomarkers for cancer diagnosis and treatment.

The arrangement includes exclusive rights to certain disease targets and non-exclusive rights to platform technologies.

NEW YORK (GenomeWeb) — Isis Pharmaceuticals and Santaris Pharma are currently negotiating a settlement to their roughly three-year-old patent-infringement lawsuit and believe there is "strong potential to settle" the litigation instead of going to trial, according to court documents filed this mo

NEW YORK (GenomeWeb) – While its primary focus remains on a class of novel cell membrane-disrupting antimicrobials, privately held Lakewood-Amedex is ramping up work on proprietary, orally delivered antisense molecules, with an eye to tackling influenza and, eventually, other viral diseases.

NEW YORK (GenomeWeb) – Marina Biotech this week took another step toward reestablishing itself as a player in the nucleic acids drug sector, regaining compliance with US Securities and Exchange Commission financial reporting requirements with the submission of the requisite information for 2012,

NEW YORK (GenomeWeb) – The National Institutes of Health this month announced two related funding opportunities for small businesses developing platform delivery technologies for nucleic acid therapeutics.

People in the News: Art Krieg

Premium

RNA drug developer Sarepta Therapeutics disclosed that its CSO, Art Krieg, has been terminated from his position at the company.
Details about the termination were not made public.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.